- Home
- PTC vs NTRA Comparison
PTC vs NTRA Comparison
Compare PTC & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTC
- NTRA
- Stock Information
- Founded
- PTC 1985
- NTRA 2003
- Country
- PTC United States
- NTRA United States
- Employees
- PTC N/A
- NTRA N/A
- Industry
- PTC Computer Software: Prepackaged Software
- NTRA Medical Specialities
- Sector
- PTC Technology
- NTRA Health Care
- Exchange
- PTC Nasdaq
- NTRA Nasdaq
- Market Cap
- PTC 24.3B
- NTRA 27.0B
- IPO Year
- PTC 1989
- NTRA 2015
- Fundamental
- Price
- PTC $177.06
- NTRA $209.47
- Analyst Decision
- PTC Buy
- NTRA Strong Buy
- Analyst Count
- PTC 13
- NTRA 18
- Target Price
- PTC $207.31
- NTRA $208.94
- AVG Volume (30 Days)
- PTC 849.7K
- NTRA 1.3M
- Earning Date
- PTC 11-05-2025
- NTRA 11-06-2025
- Dividend Yield
- PTC N/A
- NTRA N/A
- EPS Growth
- PTC 96.80
- NTRA N/A
- EPS
- PTC 6.14
- NTRA N/A
- Revenue
- PTC $2,739,226,000.00
- NTRA $2,116,676,000.00
- Revenue This Year
- PTC $3.09
- NTRA $25.70
- Revenue Next Year
- PTC $8.29
- NTRA $15.42
- P/E Ratio
- PTC $28.91
- NTRA N/A
- Revenue Growth
- PTC 19.18
- NTRA 38.17
- 52 Week Low
- PTC $133.38
- NTRA $125.38
- 52 Week High
- PTC $219.69
- NTRA $210.77
- Technical
- Relative Strength Index (RSI)
- PTC 22.37
- NTRA 76.15
- Support Level
- PTC $170.97
- NTRA $182.20
- Resistance Level
- PTC $206.57
- NTRA $203.23
- Average True Range (ATR)
- PTC 4.21
- NTRA 7.85
- MACD
- PTC -2.79
- NTRA 0.60
- Stochastic Oscillator
- PTC 16.70
- NTRA 87.72
About PTC PTC Inc.
PTC offers high-end computer-assisted design (Creo) and product lifecycle management (Windchill) software as well as Internet of Things and AR industrial solutions. Founded in 1985, PTC has 28,000 customers, with revenue stemming mostly from North America and Europe.
About NTRA Natera Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.